Axsome Therapeutics, Inc. (0HKF.L)
USD 94.11
(0.14%)
USD 94.11
(0.14%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 476.36 Million USD | 90.03% |
| 2022 | 221.34 Million USD | 77.49% |
| 2021 | 124.7 Million USD | 25.86% |
| 2020 | 99.08 Million USD | 47.66% |
| 2019 | 67.1 Million USD | 105.66% |
| 2018 | 32.62 Million USD | 21.04% |
| 2017 | 26.95 Million USD | -0.41% |
| 2016 | 27.06 Million USD | 194.35% |
| 2015 | 9.19 Million USD | 67.57% |
| 2014 | 5.48 Million USD | 198.35% |
| 2013 | 1.83 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 135.55 Million USD | -19.46% |
| 2024 Q2 | 153.14 Million USD | 15.93% |
| 2023 Q2 | 101.1 Million USD | 8.07% |
| 2023 Q4 | 168.31 Million USD | 48.45% |
| 2023 Q3 | 113.38 Million USD | 12.14% |
| 2023 Q1 | 93.55 Million USD | 20.26% |
| 2023 FY | 420.6 Million USD | 90.03% |
| 2022 Q4 | 77.79 Million USD | 35.59% |
| 2022 Q2 | 47.87 Million USD | 25.04% |
| 2022 Q1 | 38.28 Million USD | 17.42% |
| 2022 FY | 221.34 Million USD | 77.49% |
| 2022 Q3 | 57.37 Million USD | 19.84% |
| 2021 Q3 | 33.4 Million USD | 8.3% |
| 2021 Q4 | 32.6 Million USD | -2.39% |
| 2021 Q1 | 27.84 Million USD | 0.55% |
| 2021 Q2 | 30.84 Million USD | 10.79% |
| 2021 FY | 124.7 Million USD | 25.86% |
| 2020 FY | 99.08 Million USD | 47.66% |
| 2020 Q3 | 21.12 Million USD | 18.83% |
| 2020 Q2 | 17.77 Million USD | -45.28% |
| 2020 Q1 | 32.49 Million USD | 33.01% |
| 2020 Q4 | 27.69 Million USD | 31.07% |
| 2019 Q1 | 10.42 Million USD | 10.28% |
| 2019 Q4 | 24.42 Million USD | 29.88% |
| 2019 Q3 | 18.8 Million USD | 39.85% |
| 2019 FY | 67.1 Million USD | 105.66% |
| 2019 Q2 | 13.44 Million USD | 29.04% |
| 2018 FY | 32.62 Million USD | 21.04% |
| 2018 Q4 | 9.45 Million USD | 17.75% |
| 2018 Q3 | 8.02 Million USD | 0.46% |
| 2018 Q2 | 7.98 Million USD | 11.54% |
| 2018 Q1 | 7.16 Million USD | 11.16% |
| 2017 FY | 26.95 Million USD | -0.41% |
| 2017 Q1 | 7.67 Million USD | 7.28% |
| 2017 Q3 | 6.09 Million USD | -9.78% |
| 2017 Q2 | 6.75 Million USD | -12.01% |
| 2017 Q4 | 6.44 Million USD | 5.81% |
| 2016 FY | 27.06 Million USD | 194.35% |
| 2016 Q4 | 7.15 Million USD | -0.78% |
| 2016 Q3 | 7.2 Million USD | 5.57% |
| 2016 Q2 | 6.82 Million USD | 16.05% |
| 2016 Q1 | 5.88 Million USD | 86.49% |
| 2015 FY | 9.19 Million USD | 67.57% |
| 2015 Q4 | 3.15 Million USD | 55.87% |
| 2015 Q3 | 2.02 Million USD | -2.93% |
| 2015 Q2 | 2.08 Million USD | 7.85% |
| 2015 Q1 | 1.93 Million USD | -0.78% |
| 2014 FY | 5.48 Million USD | 198.35% |
| 2014 Q1 | 1.9 Million USD | 0.0% |
| 2014 Q4 | 1.94 Million USD | 14.83% |
| 2014 Q3 | 1.69 Million USD | -11.02% |
| 2014 Q2 | 1.9 Million USD | 0.0% |
| 2013 FY | 1.83 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -92.621% |
| Dynavax Technologies Corporation | 219.14 Million USD | -117.372% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 9.953% |
| Perrigo Company plc | 1.52 Billion USD | 68.835% |
| Illumina, Inc. | 3.81 Billion USD | 87.507% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 95.354% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -5.625% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.827% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 76.797% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -294.805% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 83.08% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -966.47% |
| Waters Corporation | 943.51 Million USD | 49.512% |
| Biogen Inc. | 5.2 Billion USD | 90.848% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -108.309% |
| Evolus, Inc. | 189.75 Million USD | -151.034% |
| Adicet Bio, Inc. | 152.03 Million USD | -213.316% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -234.375% |
| bluebird bio, Inc. | 240.23 Million USD | -98.292% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -75.199% |
| FibroGen, Inc. | 398.11 Million USD | -19.654% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 77.477% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3324.675% |
| Homology Medicines, Inc. | 9.87 Million USD | -4723.899% |
| Geron Corporation | 70.44 Million USD | -576.254% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 73.536% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -11.39% |
| Myriad Genetics, Inc. | 600.1 Million USD | 20.62% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -372.453% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 13.635% |
| Zoetis Inc. | 2.76 Billion USD | 82.772% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -882.145% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 56.273% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 72.721% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 90.024% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1116.663% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 38.896% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -72.786% |
| Verastem, Inc. | 92.08 Million USD | -417.31% |
| Nektar Therapeutics | 190.9 Million USD | -149.53% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -3823.565% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 64.995% |
| OPKO Health, Inc. | 574.68 Million USD | 17.11% |
| Exelixis, Inc. | 1.58 Billion USD | 69.979% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 70.162% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -29.231% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -754.365% |
| uniQure N.V. | 285.08 Million USD | -67.093% |
| Imunon, Inc. | 21.03 Million USD | -2165.099% |
| Blueprint Medicines Corporation | 722.86 Million USD | 34.101% |
| Insmed Incorporated | 949.26 Million USD | 49.818% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -59.148% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -16.525% |
| TG Therapeutics, Inc. | 198.47 Million USD | -140.01% |
| Incyte Corporation | 1.19 Billion USD | 59.986% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 54.372% |